Business Wire

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting

Share

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., will be presenting data on LACRIFILL® Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Boston, MA on April 5-8, 2024. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.

“These are truly exciting times for Nordic Pharma as we near the U.S. launch of LACRIFILL Canalicular Gel, a key milestone in our global expansion strategy,” said Charlotte Phelps, CEO of Nordic Pharma. “The recent acquisition of Visant Medical along with Amring Pharmaceuticals becoming Nordic Pharma, Inc., has increased our internal know-how and assets. And with our strong U.S. leadership team and the invaluable support of our Medical Advisory Board, I firmly believe that Nordic Pharma is well-positioned to thrive as a new specialty ophthalmic player and enhance patient care by introducing this novel therapy for dry eye.”

“As chairperson of the LACRIFILL U.S. Medical Advisory Board, I am excited about the potential of employing a cross-linked hyaluronic lacrimal filler to optimally occlude the canalicular system to maximize tear film preservation in patients with dry eye symptoms,” said Eric D. Donnenfeld, MD.

ASCRS attendees are invited to stop by booth #1245 to learn how LACRIFILL Canalicular Gel is changing practice and changing lives. Attendees will also have the opportunity to be among the first Eye Care Professionals to place orders. LACRIFILL Canalicular Gel will be featured at various Refractive and Cornea Day sessions throughout the meeting, including the “LACRIFILL: A Paradigm Shift in Dry Eye Intervention” panel, which will be held on Saturday, April 6th, 2024 and will include the distinguished faculty of Eric Donnenfeld; MD, Preeya Gupta, MD; Darrell White, MD; and Kevin J. Corcoran, COE, CPC, CPMA, FNAO and the Principal of Corcoran & Corcoran.

Mark Packer, MD, FACS, CPI, who will be moderating the panel said, “As a lacrimal filler, cross-linked hyaluronic acid provides a new approach to preservation of the tear film, protecting and conforming to delicate tissues while blocking outflow. LACRIFILL Canalicular Gel transforms treatment of the ocular surface, with demonstrated safety and effectiveness for both signs and symptoms of dry eye.”

Chief Commercial Officer of Eye Care U.S., Jai Parekh, MD, MBA said, “I am thrilled for Nordic Pharma to be presenting data on LACRIFILL Canalicular Gel at a meeting as important as ASCRS. This is where science and innovation come together, making it the perfect environment to highlight this novel therapy for dry eye.”

For more information and ordering details for LACRIFILL Canalicular Gel visit lacrifill.com.

About Nordic Group B.V.
Nordic Group B.V. is a privately owned, medium-size international pharmaceutical company which focuses on the development and commercialization of specialty products. Portfolio enhancement has been accomplished through targeted developments and focused acquisitions to build a foundation in Eye Care, Rheumatology and Women’s Health. Nordic Pharma has established deep roots throughout Europe, and more recently, expanded outside of Europe with increased acquisitions worldwide.

Nordic Pharma is a part of SEVER Life Sciences, a holding company created in 2019 that brings together three diverse but complementary companies that offer a wide range of products, pharmaceutical development services and delivery technologies.

About Nordic Pharma, Inc.
Nordic Pharma, Inc., subsidiary of Nordic Group B.V., is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.

Safe Harbor
This press release contains forward-looking statements, including, without limitation, statements related to Nordic Group /Nordic Pharma’s business developments and the implementation of Nordic Group /Nordic Pharma’s strategic initiatives. Because these statements reflect Nordic Group /Nordic Pharma’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Nordic Group /Nordic Pharma’s expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Nordic Group /Nordic Pharma, and other factors that could affect Nordic Group /Nordic Pharma’s business and financial performance. Nordic Group /Nordic Pharma does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Disclaimer
All educational content of the ASCRS Annual Meeting is planned by its program committee, and ASCRS does not endorse, promote, approve, or recommend the use of any products, devices, or services.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nordic Pharma, Inc.
Kate Popova
Contracts Administration Lead
610-285-1699
ekaterina.popova@nordicpharma.com

Gail Feerrar
Director Sales and Marketing
610-285-7152
gail.feerrar@nordicpharma.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemohim, a Functional Food to Boost Immune System, Sparks Global Sensation22.4.2024 04:59:00 CEST | Press release

Hemohim is garnering remarkable popularity in the global market as Korea's one of the leading functional foods. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418277251/en/ Kolmar BNH Sejong Factory (Photo: Kolmar BNH) Hemohim is developed through an eight-year collaboration between Kolmar BNH (KOSDAQ: 200130) and the Korea Atomic Energy Research Institute, with an investment of KRW 5 billion. It was extracted from raw materials of angelica gigas, cnidium officinale, and paeonia japonica, which have been traditionally used in herbal medicine. Kolmar BNH performed tests on humans to confirm the safety and efficacy of its main ingredient, ‘HemoHIM Extract complex of Angelica gigas, etc.’, and was recognized by the Ministry of Food and Drug Safety of Korea in 2006 for its immune-boosting properties. Distributed by Atomy, a customer of Kolmar BNH, Hemohim has sold over KRW 2 trillion worth of products in just 17 years since i

“e4life” is Present at Expomed Eurasia with its Innovative Device Able to Inactivate Flu and Covid Viruses With an Efficacy over 90%19.4.2024 17:13:00 CEST | Press release

Expomed Eurasia, the most important medical exhibition between Europe and Asia, is ready to house more than a hundred companies, to discover new technological trends and the most innovative products which are going to change deeply the health market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240419226980/en/ e4life: e4ambient and e4you devices (Photo: Business Wire) This is a perfect occasion for e4life to present its device based on the e4shield technology which is able to inactivate flu and Covid viruses present in the air. A technology, patented in Italy, that uses neither chemical agents nor filtering materials, but it is based on the transmission of electromagnetic waves able to inactivate the viral load in aerosol. “This Exhibition represents an extraordinary opportunity to present our innovative technology (e4shield) in a dynamic and rapidly evolving region as Eurasia. In a climate of growing consciousness of the

Qualcomm Schedules Second Quarter Fiscal 2024 Earnings Release and Conference Call19.4.2024 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced that it will publish the Company’s financial results for its second quarter fiscal 2024 on Wednesday, May 1, 2024, after the close of the market on the Company’s Investor Relations website, at https://investor.qualcomm.com/financial-information. The earnings release will also be furnished to the Securities and Exchange Commission (SEC) on a Form 8-K, which will be available on the SEC website at http://www.sec.gov. Qualcomm will host a conference call to discuss its second quarter fiscal 2024 results which will be broadcast live on May 1, 2024, beginning at 1:45 p.m. Pacific Time (PT) at https://investor.qualcomm.com/news-events/events. An audio replay will be available at https://investor.qualcomm.com/news-events/events and via telephone following the live call for 30 days thereafter. To listen to the replay via telephone, U.S. callers may dial (877) 660-6853 and international callers may dial (201) 612-7415. Callers should use rese

Newmont Appoints Mining Industry Veteran Francois Hardy as Chief Technology Officer19.4.2024 14:56:00 CEST | Press release

Newmont Corporation (NYSE: NEM, TSX: NGT, ASX: NEM, PNGX: NEM) today announced the appointment of Francois Hardy as Chief Technology Officer (CTO). Francois will join Newmont’s Executive Leadership Team and lead the technical work across the business to improve operational performance and drive growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240419973025/en/ Newmont Appoints Mining Industry Veteran Francois Hardy as Chief Technology Officer (Photo: Business Wire) Francois will take over from interim CTO, Dean Gehring, who also served in a dual role as Newmont’s Chief Integration Officer. After a period of transition, Dean will be leaving the company in early July. Francois brings more than 30 years of technical and operational experience in mining to the role. He commenced with Newmont in 2002 and has held roles including Group Head Exploration, Managing Director Africa and General Manager Tanami. “Francois is a stron

SLB Announces First-Quarter 2024 Results, Targeting to Return $7 Billion to Shareholders Over 2024–202519.4.2024 12:50:00 CEST | Press release

SLB (NYSE: SLB) today announced results for the first-quarter 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417469361/en/ The exterior of the SLB headquarters in Houston, Texas (Photo: Business Wire) First-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeMar. 31, 2024Dec. 31, 2023Mar. 31, 2023 SequentialYear-on-yearRevenue $8,707 $8,990 $7,736 -3% 13% Income before taxes - GAAP basis $1,357 $1,433 $1,161 -5% 17% Income before taxes margin - GAAP basis 15.6% 15.9% 15.0% -35 bps 58 bps Net income attributable to SLB - GAAP basis $1,068 $1,113 $934 -4% 14% Diluted EPS - GAAP basis $0.74 $0.77 $0.65 -4% 14% Adjusted EBITDA* $2,057 $2,277 $1,788 -10% 15% Adjusted EBITDA margin* 23.6% 25.3% 23.1% -171 bps 51 bps Pretax segment operating income* $1,649 $1,868 $1,391 -12% 19% Pretax segment operating margin* 18.9% 20.8% 18.0% -184 bps 95 bps Net income attributable to SLB, excluding cha

HiddenA line styled icon from Orion Icon Library.Eye